The Royal Marsden National Health Service (NHS) Trust, Sutton, United Kingdom.
Blood. 2011 Nov 24;118(22):5799-802. doi: 10.1182/blood-2011-08-372854. Epub 2011 Sep 26.
Intravenous alemtuzumab is an effective and well-tolerated treatment for T-cell prolymphocytic leukemia (T-PLL). Alemtuzumab given intravenously as first-line treatment in 32 patients resulted in an overall response rate of 91% with 81% complete responses. Studies in B-cell chronic lymphocytic leukemia have shown subcutaneous alemtuzumab to be equally as effective as intravenous alemtuzumab. The UKCLL05 pilot study examined the efficacy and toxicity of this more convenient method of administration in 9 previously untreated patients with T-PLL. Only 3 of 9 patients (33%) responded to treatment. Furthermore, 2 of 9 patients (22%) died while on treatment. Recruitment was terminated because of these poor results. After rescue therapy with intravenous alemtuzumab and/or pentostatin, median progression-free survival and overall survival were similar to the intravenous group. Alemtuzumab delivered intravenously, but not subcutaneously, remains the treatment of choice for previously untreated T-PLL.
静脉注射阿仑单抗是治疗 T 细胞前淋巴细胞白血病（T-PLL）的一种有效且耐受良好的方法。32 例患者作为一线治疗接受静脉注射阿仑单抗，总缓解率为 91%，完全缓解率为 81%。在 B 细胞慢性淋巴细胞白血病中的研究表明，皮下注射阿仑单抗与静脉注射阿仑单抗同样有效。英国 CLL05 试点研究在 9 例未经治疗的 T-PLL 患者中检查了这种更方便的给药方法的疗效和毒性。9 例患者中只有 3 例（33%）对治疗有反应。此外，9 例患者中有 2 例（22%）在治疗期间死亡。由于这些不良结果，招募被终止。在接受静脉注射阿仑单抗和/或喷司他丁的抢救治疗后，无进展生存期和总生存期与静脉组相似。静脉注射而非皮下注射的阿仑单抗仍然是未经治疗的 T-PLL 的首选治疗方法。
